Ascendis Pharma Valuation
| ASND Stock | USD 136.00 0.32 0.23% |
At this time, the firm appears to be overvalued. Ascendis Pharma AS shows a prevailing Real Value of $67.52 per share. The current price of the firm is $136.0. Our model approximates the value of Ascendis Pharma AS from analyzing the firm fundamentals such as profit margin of (1.54) %, and Return On Equity of -8.18 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Ascendis Pharma's valuation include:
Price Book 14.5547 | Enterprise Value 8.3 B | Enterprise Value Ebitda (20.75) | Price Sales 25.6471 | Enterprise Value Revenue 24.2148 |
Overvalued
Today
Please note that Ascendis Pharma's price fluctuation is very steady at this time. Calculation of the real value of Ascendis Pharma AS is based on 3 months time horizon. Increasing Ascendis Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Ascendis stock is determined by what a typical buyer is willing to pay for full or partial control of Ascendis Pharma AS. Since Ascendis Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ascendis Stock. However, Ascendis Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 136.0 | Real 67.52 | Target 0.34 | Hype 136.13 | Naive 135.35 |
The real value of Ascendis Stock, also known as its intrinsic value, is the underlying worth of Ascendis Pharma AS Company, which is reflected in its stock price. It is based on Ascendis Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ascendis Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ascendis Pharma AS helps investors to forecast how Ascendis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ascendis Pharma more accurately as focusing exclusively on Ascendis Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Ascendis Pharma's intrinsic value based on its ongoing forecasts of Ascendis Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Ascendis Pharma's closest peers. If more than one evaluation category is relevant for Ascendis Pharma we suggest using both methods to arrive at a better estimate.
Ascendis Pharma Cash |
|
Ascendis Valuation Trend
Comparing Ascendis Pharma's enterprise value against its market capitalization is a good way to estimate the value of Ascendis Pharma AS uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Ascendis Pharma Total Value Analysis
Ascendis Pharma AS is presently estimated to have valuation of 8.32 B with market capitalization of 8.15 B, debt of 644.26 M, and cash on hands of 955.15 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Ascendis Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.32 B | 8.15 B | 644.26 M | 955.15 M |
Ascendis Pharma Investor Information
About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 7.82. Ascendis Pharma AS had not issued any dividends in recent years. Based on the key measurements obtained from Ascendis Pharma's financial statements, Ascendis Pharma AS may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Ascendis Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ascendis Pharma has an asset utilization ratio of 32.31 percent. This indicates that the Company is making $0.32 for each dollar of assets. An increasing asset utilization means that Ascendis Pharma AS is more efficient with each dollar of assets it utilizes for everyday operations.Ascendis Pharma Ownership Allocation
The majority of Ascendis Pharma AS outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Ascendis Pharma AS to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Ascendis Pharma. Please pay attention to any change in the institutional holdings of Ascendis Pharma AS as this could imply that something significant has changed or is about to change at the company.Ascendis Pharma Profitability Analysis
The company reported the previous year's revenue of 266.72 M. Net Loss for the year was (481.45 M) with profit before overhead, payroll, taxes, and interest of 39.04 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Ascendis Pharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Ascendis Pharma and how it compares across the competition.
About Ascendis Pharma Valuation
The stock valuation mechanism determines Ascendis Pharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Ascendis Pharma. We calculate exposure to Ascendis Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ascendis Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 222.3 M | 233.4 M | |
| Pretax Profit Margin | (1.78) | (1.87) | |
| Operating Profit Margin | (1.71) | (1.79) | |
| Net Loss | (1.81) | (1.90) | |
| Gross Profit Margin | 0.83 | 0.57 |
Ascendis Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Ascendis Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 56.3 M |
Ascendis Pharma Current Valuation Indicators
Valuation refers to the process of determining the present value of Ascendis Pharma AS and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Ascendis we look at many different elements of the entity such as Ascendis's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Ascendis Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Ascendis Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Ascendis Pharma's worth.Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |